ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.

PHASE3RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Epilepsy, Generalized
Interventions
DRUG

Cenobamate

Cenobamate will be orally administered once daily.

Trial Locations (25)

Unknown

RECRUITING

Aichi Medical University Hospital, Aichi

RECRUITING

Hospital of the University of Occupational and Environmental Health, Japan, Fukuoka

RECRUITING

Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU Medical Clinic, Fukushima

RECRUITING

Local Independent Administrative Corporation Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital, Hiroshima

RECRUITING

Hokkaido University Hospital, Hokkaido

RECRUITING

Itami City Hospital, Hyōgo

RECRUITING

Tsuchiura Kyodo General Hospita, Ibaraki

RECRUITING

University of Tsukuba Hospital, Ibaraki

RECRUITING

Kagoshima University Hospital, Kagoshima

RECRUITING

SHOWA University Fujigaoka Hospital, Kanagawa

RECRUITING

Yokohama City University Hospital, Kanagawa

RECRUITING

National Hospital Organization Nishiniigata Chuo Hospital, Niigata

RECRUITING

Koide Clinic of Epilepsy and Neurological Disorders, Osaka

RECRUITING

TMG Asaka Medical Center, Saitama

RECRUITING

NHO Shizuoka Institute of Epilepsy and Neurological Disorder, Shizuoka

RECRUITING

Jichi Medical University Hospital, Tochigi

RECRUITING

Jikei University Hospital, Tokyo

RECRUITING

Maynds Tower Mental Clinic, Tokyo

RECRUITING

National Center of Neurology and Psychiatry, Tokyo

RECRUITING

Nihonbashi Neuro Clinic, Tokyo

RECRUITING

Shinjuku Neuro Clinic, Tokyo

RECRUITING

Tokyo Women's Medical University, Adachi Medical Center, Tokyo

RECRUITING

Yamaguchi Grand Medical Center, Yamaguchi

RECRUITING

University of Yamanashi Hospital, Yamanashi

RECRUITING

Yamanashi Prefectural Central Hospital, Yamanashi

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY